Medicure Inc. – TSX:MPH.V

Medicure stock price today

CAD 1.18
+0.29
+34.09%
Financial Health
0
1
2
3
4
5
6
7
8
9

Medicure stock price monthly change

-25.42%
month

Medicure stock price quarterly change

-25.42%
quarter

Medicure stock price yearly change

-37.14%
year

Medicure key metrics

Market Cap
 13.14M
Enterprise value
 N/A
P/E
 N/A
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 N/A
PEG ratio
 N/A
EPS
 -0.11
Revenue
 21.76M
EBITDA
 522K
Income
 -1.16M
Revenue Q/Q
 1.17%
Revenue Y/Y
 -5.29%
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 2.4%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Medicure stock price history

Medicure stock forecast

Medicure financial statements

Profit Margin

Medicure Inc. (TSX:MPH.V): Profit margin
Jun 2023 5.99M 253K 4.22%
Sep 2023 5.00M 84K 1.68%
Dec 2023 5.07M -1.54M -30.53%
Mar 2024 5.69M 51K 0.9%
MPH.V income statement history

Debt to Assets

Medicure Inc. (TSX:MPH.V): Debt to assets
Jun 2023 29207000 7.96M 27.26%
Sep 2023 28845000 6.97M 24.19%
Dec 2023 28059000 8.16M 29.09%
Mar 2024 28673000 8.16M 28.49%
MPH.V balance sheet history

Cash Flow

Medicure Inc. (TSX:MPH.V): Cash Flow
Jun 2023 593K 0 -75K
Sep 2023 386K -115K -74K
Dec 2023 927K -128K -72K
Mar 2024 -132K -87K -76K
MPH.V cash flow history

Medicure alternative data

Medicure
Employees

Medicure Inc. (TSX:MPH.V): Employee count
Mar 2024 25
Apr 2024 25
May 2024 25
Jun 2024 25
Jul 2024 25

Medicure other data

Frequently Asked Questions (FAQ)

  • What's the price of Medicure stock today?

    One share of Medicure stock can currently be purchased for approximately $1.18.

  • When is Medicure's next earnings date?

    Unfortunately, Medicure's (MPH.V) next earnings date is currently unknown.

  • Does Medicure pay dividends?

    No, Medicure does not pay dividends.

  • How much money does Medicure make?

    Medicure has a market capitalization of 13.14M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 5.94% to 21.69M US dollars.

  • What is Medicure's stock symbol?

    Medicure Inc. is traded on the TSX under the ticker symbol "MPH.V".

  • What is Medicure's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry.

  • How do i buy shares of Medicure?

    Shares of Medicure can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • When Medicure went public?

    Medicure Inc. is publicly traded company for more then 13 years since IPO on 6 Sep 2012.

  • What is Medicure's official website?

    The official website for Medicure is medicure.com.

  • Where are Medicure's headquarters?

    Medicure is headquartered at 2-1250 Waverley Street, Winnipeg, MB.

  • How can i contact Medicure?

    Medicure's mailing address is 2-1250 Waverley Street, Winnipeg, MB.

Medicure company profile:

Medicure Inc.

medicure.com
Exchange:

TSX

Full time employees:

0

Industry:

Drug Manufacturers—Specialty & Generic

Sector:

Healthcare

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

2-1250 Waverley Street
Winnipeg, MB R3T 6C6

:
ISIN: CA58469E4085
: